c-erbB2 and p53 expression are not associated with stage progression of gastric cancer in Britain or Japan

European Journal of Surgical Oncology

Volumn 23, Issue 4, 1997, Pages 304-309

  McCulloch, Peter ^a   Taggart, Thomas ^b   Ochiai, Atsushi ^c   O'Dowd, Gerry ^a   Nash, John ^a   Sasako, Mitsuru ^d  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

c erbB2; Gastric cancer; p53; Stage

Indexed keywords

MUTANT PROTEIN; PROTEIN P53;

ARTICLE; CANCER GROWTH; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION; HOST RESISTANCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPAN; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PRIORITY JOURNAL; RACE DIFFERENCE; REGRESSION ANALYSIS; STOMACH CANCER; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; UNITED KINGDOM;

EID: 0030768618     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(97)90669-7     Document Type: Article

References (28)

1. Waterhouse JAH. Epidemiology of gastric cancer. In: Preece PE, Cuschieri A, Wellwood TM (eds) Cancer of the Stomach. London: Grune & Stratton, 1986: Chap. 1, 1-32.
2. Tahara E. Molecular mechanisms of stomach carcinogenesis. J Cancer Res Clin Oncol 1993; 119: 265-72.
3. Tamura G, Kihana T, Nomura K, Terada M, Sugimura T, Hirohashi S. Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation polymorphism analysis. Cancer Res 1991; 51: 3056-8.
4. Kimura H, Yonemura Y, Miyazaki I. Proliferative activity in gastric cancer determined with cell cycle-related monoclonal antibodies Ki-67 and p 105: analysis by flow cytometry. J Surg Oncol 1992; 51: 174-8.
5. Mori M, Kakeji Y, Adachi Y, et al. The prognostic significance of proliferating cell nuclear antigen in clinical gastric cancer. Surgery 1993; 683-90.
6. Tsujino T, Yoshida K, Nakayama H, Ito H, Shimosato T, Tahara E. Alterations of oncogenes in metastatic tumours of human gastric carcinomas. Br J Cancer 1990; 62: 226-30.
7. Yamada Y, Yoshida T, Hayashi K, et al. p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases. Cancer Res 1991; 51: 5800-5.
8. Fielding JWL. Gastric cancer: different diseases. Br J Surg 1989; 76: 1227.
9. McCulloch P, Ochiai A. O'Dowd G, Nash J, Sasako M, Hirohashi S. Comparison of the molecular genetics of stomach cancer in Britain and Japan: c-erbB2 and p53. Cancer 1995; 75: 920-5.
10. Livingstone JI, Yasui W, Tahara E, Wastell C. Japanese and British gastric cancer - the same biological entity? Ear J Surg Oncol 1995.
11. Japanese Research Society for Gastric Cancer. Japanese Classification of Gastric Carcinoma: First English Edition. Tokyo: Kanehara. 1995.
12. Lauren P. The two histological main types of gastric carcinoma. Acta Pathol Microbiol Scand 1965; 64: 31-49.
13. Maruyama K, Miwa K. Japanese staging system for gastric cancer. Scand J Gastroenterol 1987; 22 (Suppl. 133): 22-6.
14. Shi SR, Cote C, Kalra KL, Taylor CL, Tandon AK. A technique for retrieving antigens in formalin-fixed, routinely acid decalcified celloidin-embedded human temporal bone sections for immunohistochemistry. J Histochem Cytochem 1992; 40: 787-92.
15. Sasano H, Date F, Imatani A, Asaki S, Nagura H. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol 1993; 24: 584-9.
16. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992; 50: 859-62.
17. Starzynska T. Bromley M, Ghosh A, Stern PL. Prognostic significance of p53 over-expression in gastric and colorectal carcinoma. Br J Cancer 1992; 66: 558-62.
18. Jain S, Filipe MI, Gullick WJ, Linehan J, Morris RW. c-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: an immunohistochemical study on archival material. Int J Cancer 1991; 48: 668-71.
19. Yonemura Y, Ninomiya I, Ohoyama S, et al. Expression of c-erbB-2 oncoprotein in gastric carcinomas. Cancer 1991; 67: 2914-8.
20. Sanidas EE, Filipe MI, Linehan J, Jader S, Levison DA. Expression of p53 protein and prognosis in gastric carcinoma. Gut 1993; 34: 1470.
21. Ismail T, Rowlands D, Fielding J, Hallissey M. PCNA and p53: failed markers of prognosis in gastric cancer. Br J Surg 1993; 80: 1474.
22. Uchino S, Noguchi M, Hirota T, Itabashi M, Saito T, Kobayashi M, Hirohashi S. High incidence of nuclear accumulation of p53 protein in gastric cancer. Jpn J Clin Oncol 1992; 22: 225-31.
23. Uchino S, Tsuda H, Maruyama K, et al. Over-expression of c-erbB-2 protein in gastric cancer: its correlation with long-term survival of patients. Cancer 1993; 72: 3179-84.
24. Ohguri T, Sato Y, Koizumi W, Saigenji K, Kameya T. An immunohistochemical study of c-erbB2 protein in gastric cancer and lymph node metastases. Is the c-erbB2 protein really a prognostic indicator? Int J Cancer 1993; 53: 75-9.
25. Nagata T, Ikeda M, Nakayama F. Changing state of gastric cancer in Japan. Am J Surg 1983; 145: 226-33.
26. Sedgwick DM, Akoh JA, MacIntyre IMC. Gastric cancer in Scotland: changing epidemiology, unchanging workload. Br Med J 1991; 302: 1305-7.
27. da Silva F, Fielding JWL, Craven J, Cushieri A. MRC trial of gastric cancer: morbidity and mortality after RI and R2 resections. Br J Surg 1991; 78: 1501.
28. Bonenkamp JJ, Songun I, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 345: 745-8.